Literature DB >> 16059503

When thinking of lamotrigine and valproic acid, think "pharmacokinetically"!

Andres M Kanner.   

Abstract

Entities:  

Year:  2004        PMID： 16059503      PMCID： PMC1176375          DOI： 10.1111/j.1535-7597.2004.04515.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  5 in total

1.  The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

Authors:  F Pisani; G Oteri; M F Russo; R Di Perri; E Perucca; A Richens
Journal:  Epilepsia       Date:  1999-08       Impact factor: 5.864

2.  Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group.

Authors:  E Faught; G Morris; M Jacobson; J French; C Harden; G Montouris; W Rosenfeld
Journal:  Epilepsia       Date:  1999-08       Impact factor: 5.864

3.  Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.

Authors:  A M Kanner; M Frey
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

4.  Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group.

Authors:  M J Brodie; A W Yuen
Journal:  Epilepsy Res       Date:  1997-03       Impact factor: 3.045

5.  Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy.

Authors:  Barry E Gidal; Raj Sheth; Jennifer Parnell; Kathy Maloney; Mark Sale
Journal:  Epilepsy Res       Date:  2003-12       Impact factor: 3.045
  5 in total
  6 in total

1.  Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research.

Authors:  Joseph Junior Damba; Katie Bodenstein; Paola Lavin; Jessica Drury; Harmehr Sekhon; Christel Renoux; Emilie Trinh; Soham Rej; Kyle T Greenway
Journal:  CNS Drugs       Date:  2022-09-26       Impact factor: 6.497

Review 2.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

3.  Prescription pattern of antiepileptic drugs in a tertiary care center of India.

Authors:  Rupa Joshi; Manjari Tripathi; Pooja Gupta; Sheffali Gulati; Yogendra Kumar Gupta
Journal:  Indian J Pharmacol       Date:  2020 Jul-Aug       Impact factor: 1.200

Review 4.  Lamotrigine and Stevens-Johnson Syndrome Prevention.

Authors:  Amber N Edinoff; Long H Nguyen; Mary Jo Fitz-Gerald; Erin Crane; Kyle Lewis; Samantha St Pierre; Alan D Kaye; Adam M Kaye; Jessica S Kaye; Rachel J Kaye; Sonja A Gennuso; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16

5.  Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions.

Authors:  Arne Reimers; Eirik Skogvoll; Janne Kutschera Sund; Olav Spigset
Journal:  Eur J Clin Pharmacol       Date:  2007-05-12       Impact factor: 3.064

6.  Lamotrigine-Valproic Acid Interaction Leading to Stevens-Johnson Syndrome.

Authors:  Marta Vázquez; Cecilia Maldonado; Natalia Guevara; Andrea Rey; Pietro Fagiolino; Antonella Carozzi; Carlos Azambuja
Journal:  Case Rep Med       Date:  2018-08-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.